Arrowhead Pharmaceuticals (ARWR)
(Delayed Data from NSDQ)
$19.62 USD
+0.20 (1.03%)
Updated Sep 26, 2024 03:59 PM ET
After-Market: $19.61 -0.01 (-0.05%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.62 USD
+0.20 (1.03%)
Updated Sep 26, 2024 03:59 PM ET
After-Market: $19.61 -0.01 (-0.05%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates
by Ekta Bagri
Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.
Horizon's (HZNP) Q2 Earnings and Revenues Beat, Stock Up
by Zacks Equity Research
Horizon (HZNP) beats on both earnings and revenues in Q2. Sales soared on account of the relaunch of the thyroid eye disease drug Tepezza. As a result, stock rises.
Biotech Stock Roundup: Bristol-Myers' Updates, VCNX's Disappointing Data & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FNY
Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Arrowhead (ARWR) to provide pipeline updates when it releases first-quarter fiscal 2020 results.
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
by Ekta Bagri
We take a look at companies, which have been developing treatments for various diseases using RNAi technology.
J&J Strikes Deal with argenx to Co-Develop Cancer Antibody
by Zacks Equity Research
Johnson & Johnson (JNJ) inks a global deal with Europe's argenx to jointly develop and globally commercialize the latter's prospective antibody, cusatuzumab.
Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates
by Zacks Equity Research
Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.
J&J Inks Deal With Arrowhead for Promising Liver Candidate
by Zacks Equity Research
Johnson & Johnson (JNJ) signs a licensing pact with Arrowhead to develop the latter's RNAi therapy candidate, ARO-HBV, for treating chronic hepatitis B viral infection. The deal is worth $3.7 billion.
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DWAS